Is early antiviral therapy for recurrent hepatitis C after liver transplantation superior to later treatment? The answer is no

Sustained virologic response to therapy

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence

✍ Pratima Sharma; Jorge A. Marrero; Robert J. Fontana; Joel K. Greenson; Hari Conj 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 1 views

Sustained virologic response (SVR) after antiviral therapy for recurrent hepatitis C virus (HCV) infection in liver transplant (LT) recipients is consistently lower than that achieved in non-LT patients. We evaluated efficacy and safety of pegylated interferon (IFN) and ribavirin (RBV) therapy in LT